Munich – Bioeq AG (“Bioeq”), the exclusive owner of the global commercialization rights of Formycon’s biosimilar candidate to Lucentis(R)1 (ranibizumab), informed Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY), that an exclusive strategic partnership for commercialization of FYB201 in Europe, Canada, Israel and New Zealand has been concluded with Teva Pharmaceutical Industries Ltd. (“Teva”).

Teva Pharmaceutical Industries Ltd. is a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area and one of the largest and most complex supply chains in the pharmaceutical industry.

The submission of the marketing authorization for FYB201 to the European Medicines Agency (EMA) is expected to take place contemporarily.

1)Lucentis(R) is a registered trademark of Genentech Inc.